WillItSurvive
Medical technology and health companies · China

Airdoc

airdoc.com ↗

Chinese company using AI and retinal photos to screen for eye and systemic disease risk.

Losing its protection
Assessed 30 July 2026 · Evidence as of 30 July 2026
The structural protection is eroding.
On the recordSince 30 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: H1 2026 results, which will show whether 2025 revenue growth was real or just cost cutting
The call

Airdoc's regulatory approvals keep foreign AI out, but its own early investor Ping An has the money and reach to copy its playbook at home.

Airdoc makes artificial intelligence software that diagnoses eye diseases from retina photos. It has official Chinese government permission (Class III clearance) that keeps generic AI tools and foreign competitors out, plus hospitals and government programs that lock it in as their choice. The real problem: Ping An, which invested early and runs a huge insurance and health business in China, can follow the same government approval path and has way more money and existing customer reach to beat Airdoc at its own game. Sales have gone sideways for two years, and the company only barely broke even in early 2025 by cutting costs, not by winning more customers. The one thing that could change everything is if Ping An makes a big move in diagnostic AI (a product launch, a buyout, or a partnership) that shows it is serious about taking over Airdoc's business.

Why
01
AI pressure: Generic vision AI models from labs like Google DeepMind or OpenAI. China's Class III device approval rules keep foreign AI labs out of diagnostics, so the near threat is cheaper cameras, not smarter models. Could AI do the core job? Only partly.
02
Bigger players: Ping An. Ping An backed Airdoc early and has the capital, insurance distribution, and no regulatory blocker to build a rival retinal AI product. Could a giant copy it? Probably.
03
What protects it. NMPA Class III clearances plus years of hospital and government screening contracts that a new entrant cannot copy quickly.
What would change this call
Ping An announces a retinal or diagnostic AI product launch, acquisition, or partnership within the next year. Would show the un-blocked, better-capitalized predator is directly entering Airdoc's market.
Airdoc's H1 2026 results (due around August 2026) show revenue growth or decline versus H1 2025. Would show whether FY2025's revenue uptick and near-breakeven were sustainable growth or one-time cost cuts.
Airdoc's newly appointed auditor (replacing EY) issues its first opinion for FY2026. Would show whether governance and financial-control concerns are resolved or worsening.
Key numbers
  • FY2025 revenue RMB173.3M, up 10.8% YoY (2025-12-31)
  • FY2025 net loss narrowed to RMB24.4M from RMB265.1M (2025-12-31)
  • Cash fell to RMB580.4M from RMB683.2M (2025-12-31)
Named risks
  • Auditor non-reappointment (EY dropped for FY2026) raises governance and audit-quality concerns. Severity: high
  • Un-blocked domestic predator Ping An could launch competing retinal AI with superior capital and distribution. Severity: high
  • Revenue remains flat-to-declining over 2023-2025 with 2025 growth achieved partly via cost-cutting, not clear demand growth. Severity: medium
  • PRC regulator can abruptly reclassify device categories, as happened to laser myopia devices in July 2024, cutting revenue and triggering impairment. Severity: medium
  • Hardware quality trails rival Phelcom benchmark, risking loss of screening volume to better-performing devices. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Ping AncontestingEarly investor since January 2019 with vastly larger capital and insurance distribution, could replicate NMPA pathway
Phelcom (Eyer)losing to2024-06-14 peer-reviewed benchmark found Airdoc camera had 16.3 percent insufficient-image rate vs Phelcom's 3.1 percent
Digital Diagnostics (formerly IDx)contestingFDA De Novo-cleared LumineticsCore since 2018, competes globally in AI diabetic retinopathy screening
EyenukcontestingEyeArt system FDA-cleared August 2020, rival AI retinal screening product
Questions people ask
Is Airdoc profitable in 2026?
Airdoc narrowed its net loss to RMB24.4 million in FY2025 from RMB265.1 million in FY2024, and posted a small H1 2025 net profit of about RMB0.4 to 0.5 million versus an RMB81.5 million loss in H1 2024, per its March 2026 annual results filing.
Is Airdoc's revenue growing?
FY2025 revenue was RMB173.3 million, up 10.8 percent year on year from RMB156.4 million in FY2024, but that followed a decline from RMB204.0 million in FY2023, so growth is recent and modest, per Airdoc's March 2026 HKEX annual results.
Who is Airdoc's biggest competitor?
Ping An, an early Series B plus investor in Airdoc via its Global Voyager Fund since January 2019, runs a far larger health tech and insurance ecosystem and could replicate Airdoc's NMPA regulatory pathway without the same foreign-entrant barriers.
Could AI models replace Airdoc's diagnostic products?
Generic AI vision models are largely blocked from replacing Airdoc in China because its retinal diagnostics require NMPA Class III clearance, which Airdoc has held since August 2020 for diabetic retinopathy screening, a regulatory barrier foreign AI labs have not cleared.
Who owns Airdoc and is it publicly traded?
Airdoc has traded on the Hong Kong Stock Exchange as 2251.HK since its IPO on 5 November 2021, with Ping An Global Voyager Fund and CITIC having led a Series B plus round in January 2019 before listing.
Why did Airdoc's net loss spike in 2024?
Airdoc posted a RMB265.1 million net loss in FY2024, largely due to a goodwill impairment tied to its 2022 Beijing Zhitong acquisition after a July 2024 PRC regulatory reclassification of laser based myopia treatment devices required Class III certification.
Timeline
  • 2026-05-25Board resolves not to reappoint Ernst and Young as auditor for FY2026
  • 2026-03-31FY2025 annual results: revenue RMB173.3M, net loss narrowed to RMB24.4M
  • 2025-08-20H1 2025 update shows swing to small net profit versus RMB81.5M H1 2024 loss
  • 2025-07-30Airdoc signs agreement to acquire 30 percent stake in subsidiary for ~RMB38.4M
  • 2025-04Airdoc AIFUNDUS 2.0 obtains NMPA registration for hypertensive retinopathy and AMD
  • 2025-03-11Profit warning cites myopia device reclassification and goodwill impairment
  • 2025-01New generation AI FUNDUSCAMERA P series launched
  • 2024-12PBM LED myopia light therapy device receives regulatory approval
  • 2024-07PRC reclassifies laser based myopia devices, requiring Class III certification
  • 2021-11-05Airdoc IPOs on HKEX under ticker 2251.HK
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources